1 张晓彤, 李龙芸.表皮生长因子受体酪氨酸激酶抑制剂抗肿瘤治疗的临床进展[J]. 中国肺癌杂志, 2002;5:310-2 2 陈青, 陈宝安.新型酪氨酸激酶抑制剂 STI571[J]. 中国肿瘤临床与康复, 2002;9:127-9 3 彭涛, 周家驹.酪氨酸激酶抑制剂的研究新进展[J]. 化学进展, 2002;14:355-9 4 Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, et al.ZD1839(Iressa):an orally active inhibitor of epidermal growth factor signaling with potential for cancer thera-py[J]. Cancer Res, 2002;62:5749-54 5 杨翠香, 陈婉蓉.MTT 法检测丙烯酰胺对神经细胞的毒性作用[J]. 上海铁道大学学报, 1998;19:8-10 6 Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M, et al.ZD1839 (Iressa) induces antiangiogenic effects throughinhibitionof epidermal growth factor receptor tyrosine ki-nase[J]. Cancer Res, 2002;62:2554-60 7 Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, et al.The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo[J]. Molecular Cancer Therapeutics, 2001;1:85-94 8 张敏, 张新, 白春.表皮生长因子受体与酪氨酸激酶抑制剂在肿瘤防治中的应用进展[J]. 中国癌症杂志, 2003;13:275-8 9 Fortunato C, Rosa C, Roberto B, Vincenzo D, Grazia P, Sabi-no De Placido, et al.Antitumor effect and potentiation of cyto-toxic drugs activity in human cancer cells by ZD1839(Iressa), an epidermal growth factor receptor-selective tyrosine kinase in-hibitor[J]. Clin Cancer Res, 2000;6:2053-63 10 Lichtner RB, Menrad A, Sommer A, Klar U, Schneider MR. Signaling-inactive epidermal growth factor receptor/ ligand com-plexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors[J]. Cancer Res, 2001;61:5790-5 11 Laurent FH, Andrew P, Thomas, Craig J, Elaine SE, et al. Design and structure-activity relationship of a new class of po-tent VEGF receptor tyrosine kinase inhibitors[J]. JMedChem, 1999;42:5369-89 12 Smaill JB, Palmer BD, Rewcastle GW, Denny WA, McNama-ra DJ, Dobrusin EM, et al.Tyrosine kinase inhibitors, 15′4-(Phenylamino) quinazoline and 4-(phenylamino) pyrido[d] pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor[J]. J Med Chem, 1999;42:1083-115 13 Sirotnak FM, Zakowski MF, Miller VA, Scher HI, KrisMG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase[J]. Clin Cancer Res, 2000;6:4885-92 14 Moasser MM, Basso A, Averbuch SD, Rosen N.The tyrosine kinase inhibitor ZD1839 (“ Iressa”) inhibits HER2-driven sig-naling and suppresses the growth of HER2-overexpressing tumor cells[J]. Cancer Res, 2001;61:7184-8 |